Regnase-1 in microglia negatively regulates high mobility group box 1-mediated inflammation and neuronal injury

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Liu, Xiao Xi ^a   Wang, Chen ^a,b   Huang, Shao Fei ^a   Chen, Qiong ^a   Hu, Ya Fang ^a   Zhou, Liang ^a   Gu, Yong ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HBP1 PROTEIN, RAT; HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 PROTEIN, HUMAN; HMGB1 PROTEIN, MOUSE; RECOMBINANT PROTEIN; RIBONUCLEASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; ZC3H12A PROTEIN, HUMAN; ZC3H12A PROTEIN, MOUSE; ZC3H12A PROTEIN, RAT;

ANIMAL; BRAIN; CELL CULTURE; CENTRAL NERVOUS SYSTEM; GENE EXPRESSION REGULATION; INFLAMMATION; MALE; METABOLISM; MICROGLIA; MOUSE; NERVE CELL; RAT; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; BRAIN; CELL LINE, TUMOR; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM; CYTOKINES; GENE EXPRESSION REGULATION; HMGB1 PROTEIN; INFLAMMATION; MALE; MICE; MICROGLIA; NEURONS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; RIBONUCLEASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84962632372     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24073     Document Type: Article

References (54)

1. Amor, S. et al. Inflammation in neurodegenerative diseases-an update. Immunology 142, 151-66 (2014).
2. Barone, F. C. & Feuerstein, G. Z. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 19, 819-34 (1999).
3. Das, M., Mohapatra, S. & Mohapatra, S. S. New perspectives on central and peripheral immune responses to acute traumatic brain injury. J Neuroinflammation 9, 236 (2012).
4. Heneka, M. T. et al. Neuroinflammation in Alzheimer's disease. The Lancet Neurology 14, 388-405 (2015).
5. Stone, D. K., Reynolds, A. D., Mosley, R. L. & Gendelman, H. E. Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal 11, 2151-66 (2009).
6. Sta, M. et al. Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol Dis 42, 211-20 (2011).
7. Bianchi, M. E. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81, 1-5 (2007).
8. Chen, G. Y. & Nunez, G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10, 826-37 (2010).
9. Kang, R. et al. HMGB1 in health and disease. Mol Aspects Med 40, 1-116 (2014).
10. Kim, J. B. et al. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 26, 6413-21 (2006).
11. Muhammad, S. et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 28, 12023-31 (2008).
12. Okuma, Y., Date, I. & Nishibori, M. [Anti-high mobility group box-1 antibody therapy for traumatic brain injury]. Yakugaku Zasshi 134, 701-5 (2014).
13. Jang, A. et al. p35 deficiency accelerates HMGB-1-mediated neuronal death in the early stages of an Alzheimer's disease mouse model. Curr Alzheimer Res 10, 829-43 (2013).
14. Takata, K. et al. High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. J Neurosci Res 78, 880-91 (2004).
15. Gao, H. M. et al. HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci 31, 1081-92 (2011).
16. Lindersson, E. K. et al. alpha-Synuclein filaments bind the transcriptional regulator HMGB-1. Neuroreport 15, 2735-9 (2004).
17. Andersson, A. et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol 84, 1248-55 (2008).
18. Yang, H. & Tracey, K. J. High mobility group box 1 (HMGB1). Crit Care Med 33, S472-4 (2005).
19. Fang, P., Schachner, M. & Shen, Y. Q. HMGB1 in development and diseases of the central nervous system. Mol Neurobiol 45, 499-506 (2012).
20. Matsushita, K. et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 458, 1185-90 (2009).
21. Kasza, A. et al. Transcription factors Elk-1 and SRF are engaged in IL1-dependent regulation of ZC3H12A expression. BMC Mol Biol 11, 14-24 (2010).
22. Uehata, T. et al. Malt1-induced cleavage of regnase-1 in CD4(+ ) helper T cells regulates immune activation. Cell 153, 1036-49 (2013).
23. Yang, C., Huang, S., Wang, X. & Gu, Y. Emerging Roles of CCCH-Type Zinc Finger Proteins in Destabilizing mRNA Encoding Inflammatory Factors and Regulating Immune Responses. Crit Rev Eukaryot Gene Expr 25, 77-89 (2015).
24. Mino, T. et al. Regnase-1 and Roquin Regulate a Common Element in Inflammatory mRNAs by Spatiotemporally Distinct Mechanisms. Cell 161, 1058-73 (2015).
25. Mizgalska, D. et al. Interleukin-1-inducible MCPIP protein has structural and functional properties of RNase and participates in degradation of IL-1beta mRNA. Febs j 276, 7386-99 (2009).
26. Liang, J. et al. A novel CCCH-zinc finger protein family regulates proinflammatory activation of macrophages. J Biol Chem 283, 6337-46 (2008).
27. Zhou, L. et al. Monocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction. Circ Res 98, 1177-85 (2006).
28. Skalniak, L. et al. Regulatory feedback loop between NF-kappaB and MCP-1-induced protein 1 RNase. Febs j 276, 5892-905 (2009).
29. Jin, Z., Liang, J., Wang, J. & Kolattukudy, P. E. MCP-induced protein 1 mediates the minocycline-induced neuroprotection against cerebral ischemia/reperfusion injury in vitro and in vivo. J Neuroinflammation 12, 264 (2015).
30. Jin, Z., Liang, J., Wang, J. & Kolattukudy, P. E. Delayed brain ischemia tolerance induced by electroacupuncture pretreatment is mediated via MCP-induced protein 1. J Neuroinflammation 10, 63 (2013).
31. Liang, J. et al. Participation of MCP-induced protein 1 in lipopolysaccharide preconditioning-induced ischemic stroke tolerance by regulating the expression of proinflammatory cytokines. J Neuroinflammation 8, 182 (2011).
32. Yao, H. et al. MiR-9 promotes microglial activation by targeting MCPIP1. Nat Commun 5, 4386 (2014).
33. Andersson, U. et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192, 565-70 (2000).
34. Louw, A. M. et al. Chitosan polyplex mediated delivery of miRNA-124 reduces activation of microglial cells in vitro and in rat models of spinal cord injury. Nanomedicine (2015).
35. Kumar, A., Bhatia, H. S., de Oliveira, A. C. & Fiebich, B. L. microRNA-26a modulates inflammatory response induced by toll-like receptor 4 stimulation in microglia. J Neurochem 135, 1189-202 (2015).
36. Saba, R. et al. MicroRNA 146a (miR-146a) is over-expressed during prion disease and modulates the innate immune response and the microglial activation state. PLoS One 7, e30832 (2012).
37. Cardoso, A. L., Guedes, J. R., Pereira de Almeida, L. & Pedroso de Lima, M. C. miR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production. Immunology 135, 73-88 (2012).
38. Zhang, Y. et al. TIPE2, a novel regulator of immunity, protects against experimental stroke. J Biol Chem 287, 32546-55 (2012).
39. Colleran, A. et al. Autophagosomal IkappaB alpha degradation plays a role in the long term control of tumor necrosis factor-alphainduced nuclear factor-kappaB (NF-kappaB) activity. J Biol Chem 286, 22886-93 (2011).
40. Lu, B. et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488, 670-4 (2012).
41. Bonaldi, T. et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. The EMBO journal 22, 5551-60 (2003).
42. Tang, D. et al. Nuclear heat shock protein 72as a negative regulator of oxidative stress (hydrogen peroxide)-induced HMGB1 cytoplasmic translocation and release. J Immunol 178, 7376-84 (2007).
43. Kim, I. D., Luo, L., Lee, H. B., Lee, H. K. & Lee, J. K. HMGB1-binding heptamer suppresses the synergistic effect of HMGB1 and LPS by interacting directly with HMGB1. Neurosci Lett 593, 40-4 (2015).
44. Liu, K. et al. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 21, 3904-16 (2007).
45. Wu, C.-X. et al. Inhibition effect of glycyrrhizin in lipopolysaccharide-induced high-mobility group box 1 releasing and expression from RAW264.7 cells. Shock (Augusta, Ga ) 43, 412-21 (2015).
46. Musumeci, D., Roviello, G. N. & Montesarchio, D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacology & therapeutics 141, 347-57 (2014).
47. Ghosh, M., Subramani, J., Rahman, M. M. & Shapiro, L. H. CD13 restricts TLR4 endocytic signal transduction in inflammation. J Immunol 194, 4466-76 (2015).
48. Liang, J. et al. MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-kappaB signaling. J Exp Med 207, 2959-73 (2010).
49. Huang, S. et al. MCPIP1 negatively regulates toll-like receptor 4 signaling and protects mice from LPS-induced septic shock. Cell Signal 25, 1228-34 (2013).
50. O'Neill, S. et al. Heat shock protein 90 inhibition abrogates TLR4-mediated NF-kappaB activity and reduces renal ischemiareperfusion injury. Sci Rep 5, 12958 (2015).
51. Izuishi, K. et al. Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol 176, 7154-8 (2006).
52. Aneja, R. K. et al. Preconditioning with high mobility group box 1 (HMGB1) induces lipopolysaccharide (LPS) tolerance. J Leukoc Biol 84, 1326-34 (2008).
53. Hu, X. et al. Preconditioning with high mobility group box 1 protein protects against myocardial ischemia-reperfusion injury. Int J Cardiol 145, 111-2 (2010).
54. Wu, H. et al. Preconditioning with recombinant high-mobility group box 1 protein protects the kidney against ischemia-reperfusion injury in mice. Kidney Int 85, 824-32 (2014).